Study Phase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Patients Following Participation in an Intensive, Non-Pharmacologic Weight Loss Program

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNutritional and Metabolic DiseasesEnrollment561% Female76%% White98%
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMAT-OBES-004Data PartnerJohnson & JohnsonCondition StudiedObesityMean/Median Age (Years)43.8

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.